For the pharmaceutical industry, microneedles are not merely a beauty tool; they represent a paradigm shift in the way drugs are delivered. They have the potential to address numerous issues with traditional drug administration methods, such as the liver first-pass effect and low bioavailability of orally administered drugs, as well as the pain and poor patient compliance associated with injection-based administration. This could open up entirely new research paths and commercial opportunities for biologics, vaccines, and drugs for chronic diseases.

Microneedles, as the most advanced form of transdermal drug delivery systems (TDDS), have the greatest advantage in bypassing the first-pass effect of the liver and the degradation in the gastrointestinal tract, allowing drugs to be directly delivered to the dermal microcirculation, significantly enhancing the bioavailability of the drugs. This is particularly important for biological macromolecular drugs such as proteins, peptides, antibodies, etc., as these drugs usually cannot be effectively absorbed orally and are sensitive to enzymatic degradation. Studies have shown that the microneedle platform can effectively deliver insulin, GLP-1 receptor agonists, monoclonal antibodies, and even cancer vaccines. It has great potential in improving the thermal stability of drugs, eliminating medical sharp waste, and reducing the reliance on cold chain storage.

In 2026, China witnessed a significant milestone in microneedle drug research: the clinical application of the dexmedetomidine hydrochloride microneedle patch submitted by Guangzhou Xinji Pharmaceutical was approved. This is the first drug microneedle patch in China to be approved for clinical trials. The product is intended for preoperative sedation in children, replacing the terrifying injection with a painless application method, precisely addressing the clinical needs of pediatric patients. Dr. Wu Chuanbin, the chairman of Xinji Pharmaceutical, stated that its microneedle drug delivery platform has established pipelines covering multiple areas such as pediatric drugs, elderly drugs, oncology, and metabolic diseases, indicating that the research on microneedle preparations is blossoming comprehensively.

Internationally, Daewoong Pharmaceutical of South Korea has made a bold announcement that its first global microneedle therapy drug is about to be launched. The aim is to improve patient compliance by eliminating injection anxiety and reducing the need for hospital visits. This marks that major multinational pharmaceutical companies have officially incorporated microneedle technology into their core innovation pipeline.

The current frontier of microneedle drug research focuses on "intelligence." For instance, a team from Peking Union Medical College Hospital and Beijing University of Chemical Technology jointly developed a near-infrared light-activated lidocaine microneedle patch. This innovative design combines photothermal materials (MXene) with the local anesthetic lidocaine. By exposing it to external near-infrared light, local heat is triggered, allowing for precise control of the rapid release of the drug within 5 minutes, enabling on-demand and rapid local anesthesia. This provides a model for the design of intelligent drug delivery devices.

Another cutting-edge direction is the integration of diagnosis and treatment. Microneedles not only deliver drugs but can also be used for biosensing and diagnosis. Researchers have developed microneedle sensors that can monitor the glucose level in interstitial fluid, as well as porous microneedle patches that can quickly detect the nitrite content in food. In the future, "closed-loop systems" integrating delivery and monitoring functions will become a reality, such as smart microneedle patches that can monitor blood sugar in real time and automatically release insulin, truly enabling the autonomous management of chronic diseases.

However, the industrialization of microneedle drugs still faces challenges. As a drug-device combination product, its regulatory path is complex and there is currently a lack of unified international standards. Cost control during large-scale production, process stability, and the accuracy of drug loading are also technical obstacles that must be overcome. Nevertheless, with enterprises like Shielongkang in Wenzhou achieving a leap in production capacity and qualification rate with the "one-step molding process," as well as enterprises like Zhongke Microneedles establishing large-scale GMP production lines, the industrialization foundation of microneedle drugs is becoming increasingly solid. This revolution in drug delivery driven by microneedles is turning more "impossible" administration methods into reality, ultimately benefiting patients worldwide.